U.S. District Court for the Eastern District of Virginia has ruled in the favor of Pfizer against generic drug maker Synthon in a patent infringement case involving Pfizer’s hypertension drug Norvasc. The court found that Synthon obtain by inequitable conduct two U.S. patents alleged to cover a process and an intermediate compound used to make the amlodipine besylate. Pfizer said the court issued a ruling that Synthon knowingly withheld from the U.S. Patent Office Pfizer publications and other information that described the process for which Synthon was seeking a patent.
No comments:
Post a Comment